GLOBAL GERIATRIC MEDICINES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

Another critical driver for the geriatric medicines market is need for improved medication management among elderly individuals. Due to factors like reduced cognitive abilities, reduced organ function and higher vulnerabilities, medication regimens for senior citizens need to be designed very carefully. Issues pertaining to medication adherence, risk of adverse drug reactions and drug-drug interactions are much more common among geriatric patients on polypharmacy schedules. Factors like vision or hearing impairments can also negatively impact their ability to follow prescriptions properly, leading to treatment failures or health complications. There is growing emphasis on developing safer, easier to administer and more effective therapeutic solutions for this patient segment. Pharmaceutical companies are increasingly focusing on new delivery mechanisms, single pill combinations, customized dosing frequencies and diagnostics to facilitate optimized treatment support for the elderly population. This helps address an important clinical challenge and presents an opportunity for enhanced medical management of older demographics through innovation in geriatric drug formulations and solutions.

• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Janssen Pharmaceuticals
• Sun Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Boehringer Ingelheim
• Eli Lilly and Company
• Bristol Myers Squibb
• Daiichi Sankyo Company, Limited
• Bausch Health Companies
• Mallinckrodt Pharmaceuticals
• Endo Pharmaceuticals
• Eisai Co., Ltd.
• Ferring Pharmaceuticals
• UCB
• Evoke Pharma
• Cadila Pharmaceuticals